The patent was filed with the US Patent and Trademark Office (USPTO).
In 2021, the company outlined how it was granted US patent #11,090,332 on composition of matter of survivin modified-mRNA, a novel way of leveraging cellular therapy to 'teach' the immune system to seek and destroy cancer.
The current patent covers specific types of dendritic cells, means of generating specialized dendritic cells, and the planned formulation that will enter clinical trials, it said. The patent application protects the use of its patented survivin mRNA both as a stand-alone vaccine and as an immunotherapy.
"We are proud of our collaborators and colleagues who have worked on our first issued survivin patent, which was filed in 2015, before the world realized the potency of modified-mRNA technology that was first successfully commercialized with the COVID-19 vaccines by Moderna and Pfizer," commented Dr David Koos, CEO of Regen BioPharma. "The currently filed application discloses means of significantly increasing efficacy by combining modified-mRNA with unique cellular immunotherapy as well as adjuvant approaches. We chose this strategy to maximally protect our intellectual property around this potentially very valuable mRNA cancer immunotherapy vaccine."
Immunotherapy of cancer represents a very large market which is currently being led by checkpoint inhibitors and CAR-T cells.
Regen BioPharma is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials, with a particular emphasis on mRNA and small molecule therapies for treating cancer and autoimmune disorders.
